Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2017

  • ID: 4318708
  • Drug Pipelines
  • 41 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ProteoThera Inc
  • XL-protein GmbH
  • MORE
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'Interleukin 1 Receptor Type 1 - Pipeline Review, H1 2017'; Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways.

The report 'Interleukin 1 Receptor Type 1 - Pipeline Review, H1 2017' outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Cardiovascular, Central Nervous System, Musculoskeletal Disorders and Oncology which include indications Rheumatoid Arthritis, Inflammation, Gouty Arthritis (Gout), Metastatic Breast Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Ductal Adenocarcinoma and Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
  • The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ProteoThera Inc
  • XL-protein GmbH
  • MORE
  1. Introduction
  2. Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Overview
  3. Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Companies Involved in Therapeutics Development
  14. Paras Biopharmaceuticals Finland Oy
  15. ProteoThera Inc
  16. Swedish Orphan Biovitrum AB
  17. XL-protein GmbH
  18. Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Drug Profiles
  19. anakinra - Drug Profile
  20. Product Description
  21. Mechanism Of Action
  22. R&D Progress
  23. anakinra biosimilar - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. Fusion Protein to Antagonize IL-1R1 for Inflammation - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. Fusion Protein to Antagonize IL1R1 for Rheumatoid Arthritis - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. PRT-1000 - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. XL-130 - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Dormant Products
  44. Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Discontinued Products
  45. Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Product Development Milestones
  46. Featured News & Press Releases
  47. May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease
  48. Jan 11, 2017: First patient randomized in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
  49. Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
  50. Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
  51. Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
  52. Apr 23, 2014: First treatment for babies with ultra-rare spectrum of autoinflammatory diseases now available in UK
  53. Dec 06, 2013: First treatment for infants with ultra-rare spectrum of autoinflammatory diseases licensed in UK
  54. Sep 19, 2013: Swedish Orphan Biovitrum Receives CHMP Positive Opinion For Treatment Of Cryopyrin-Associated Periodic Syndrome
  55. Jun 11, 2013: Sobi Gets FDA Approval To Manufacture Substance For Kineret With Partner Boehringer Ingelheim
  56. Apr 18, 2013: Topical Use Of Arthritis Drug Provides Relief For Dry Eye Disease, Study Finds
  57. Jan 23, 2013: Sobi Receives EMA Approval To Manufacture Kineret Drug Substance With Partner Boehringer Ingelheim
  58. Jan 08, 2013: Sobi's Kineret Receives FDA Approval For Treatment Of Neonatal-onset Multisystem Inflammatory Disease
  59. Nov 19, 2012: Sobi Files To Expand Kineret Label To Include CAPS
  60. Jul 06, 2012: Sobi Files For NOMID Indication For Kineret In US
  61. Aug 26, 2010: Swedish Orphan Biovitrum Receives FDA Orphan Drug Designation For Kineret
  62. Appendix
  63. Methodology
  64. Coverage
  65. Secondary Research
  66. Primary Research
  67. Expert Panel Validation
  68. Contact Us
  69. Disclaimer
List of Tables
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products under Investigation by Universities/Institutes, H1
  7. Products under Investigation by Universities/Institutes, H1
  8. Number of Products by Stage and Mechanism of Actions, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Pipeline by Paras Biopharmaceuticals Finland Oy, H1
  12. Pipeline by ProteoThera Inc, H1
  13. Pipeline by Swedish Orphan Biovitrum AB, H1
  14. Pipeline by XL-protein GmbH, H1
  15. Dormant Products, H1
  16. Dormant Products, H1 2017 (Contd..1), H1
  17. Discontinued Products, H1
List of Figures
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Molecule Types, H1
  8. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Paras Biopharmaceuticals Finland Oy
  • ProteoThera Inc
  • Swedish Orphan Biovitrum AB
  • XL-protein GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll